Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin

• Autor(es):

  Vilar, Fernando Crivelenti (University of São Paulo. Faculty of Medicine of Ribeirão Preto. Department of Internal Medicine. Division of Infectious and Tropical Diseases);

  Castro, Gleusa de (University of São Paulo. Faculty of Medicine of Ribeirão Preto. Department of Internal Medicine. Division of Infectious and Tropical Diseases);

  Moya, Maria Janete (University of São Paulo. Faculty of Medicine of Ribeirão Preto. Department of Internal Medicine. Division of Infectious and Tropical Diseases);

  Martinelli, Ana de Lourdes Candolo (University of São Paulo. Faculty of Medicine of Ribeirão Preto. Department of Internal Medicine. Division of Gastroenterology);

  Santis, Gil Cunha De (Hemocentro Foundation);

  Cozac, Ana Paula Costa Nunes da Cunha (Hemocentro Foundation);

  Figueiredo, José Fernando de Castro (University of São Paulo. Faculty of Medicine of Ribeirão Preto. Department of Internal Medicine. Division of Infectious and Tropical Diseases).

• Fonte:

  Revista da Sociedade Brasileira de Medicina Tropical; volume 40, número 6, páginas 678-680. Dezembro 2007.

• Assuntos:

  Hemolytic anemia;

  Treatment;

  Hepatitis C;

  Pegylated alpha-2a interferon;

  HIV/AIDS.

• Resumo:

  Two cases of autoimmune hemolytic anemia that occurred during the treatment of chronic hepatitis C with pegylated alpha-2a interferon and ribavirin, in HIV coinfected patients, are presented and described. The late occurrence (after six months of therapy) of this severe hemolytic anemia leads to the recommendation that hemoglobin levels should be monitored throughout the treatment period, even among patients who presented stable hemoglobin levels in the preceding months.

• Acesse o texto completo (Inglês)